替吉奥联合周疗法紫杉醇脂质体治疗晚期胃癌的临床分析  

S-1 Combined with Weekly Paclitaxel Liposome Chemotherapy in the Treatment of Advanced Gastric Cancer

作　　者：朱亚军 庄志祥[2] 陈蕾[2] 王兵 

机构地区：[1]张家港市澳洋医院肿瘤中心,江苏张家港215600 [2]苏州大学附属第二医院肿瘤科,江苏苏州215004

出　　处：《肿瘤基础与临床》2015年第5期398-401,共4页journal of basic and clinical oncology

摘　　要：目的探讨替吉奥联合周疗法紫杉醇脂质体治疗晚期胃癌的疗效及毒副反应。方法 26例晚期胃癌患者接受替吉奥胶囊和周疗法紫杉醇脂质体联合化疗,每6周为1周期,每周期评估疗效,包括有效率、疾病无进展生存期、总生存期,同时评估化疗的毒副反应。结果 26例患者中,CR 0例,PR 9例,SD 14例,PD 3例,有效率为34.6%,疾病控制率为88.5%,中位无进展生存期为6.0个月,中位生存期为10.0个月。主要毒副反应为骨髓抑制和胃肠道反应,Ⅲ、Ⅳ度毒副反应包括中性粒细胞减少2例(7.7%),恶心呕吐1例(3.9%)和腹泻1例(3.9%)。结论替吉奥联合周疗法紫杉醇脂质体治疗进展期胃癌疗好,毒副反应轻,可推荐为晚期胃癌尤其是年老体弱患者的治疗选择。Objective To investigate the efficacy and toxicities of S-1 combined with weekly paclitaxel liposome chemotherapy in the treatment of advanced gastric cancer. Methods Twenty-six patients with advanced gastric cancer were treated with S-1 combined with paclitaxel liposome. Six weeks administration was considered as one cycle. The ef-ficacy including the response rate,the progression-free survival and the overall survival as well as toxicities were evalua-ted every cycle. Results The response rate was 34. 6%,and the disease control rate was 88. 5%（ CR in the 0 pa-tient,PR in the 9 patients,SD in the 14 patients and PD in the 3 patients）. The median progression-free survival and o-verall survival time was 6. 0 and 10. 0 months,respectively. The main toxicities were hematological toxicity and gastro-intestinal reaction. GradeⅢandⅣtoxicities included 2 cases（7. 7%）of neutropenia,1 case（3. 9%）of nausea and vomiting and 1 case（3. 9%）of diarrhea. Conclusion S-1 combined with weekly paclitaxel liposome is effective and well tolerated for patients with advanced gastric cancer.

关 键 词：晚期胃癌 替吉奥 紫杉醇脂质体 周疗法 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]